The U.S. Department of Veterans Affairs (VA) has awarded Horizon Therapeutics USA, Inc. a $25.86 million Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This multiple award contract, effective from August 2019 through August 2025, allows VA medical centers and Veterans Integrated Service Networks (VISNs) to efficiently procure specialty medications from Horizon's portfolio, including KRYSTEXXA, a treatment for chronic gout. The VA has placed numerous firm fixed-price delivery orders against this FSS contract, typically ranging from $30,000 to $100,000, to acquire KRYSTEXXA and support healthcare services for veterans.
In addition to the FSS contract, Horizon holds a $31.375 million single-award Blanket Purchase Agreement (BPA) with the VA's National Acquisition Center, also under the Pharmaceuticals and Drugs FSS. This BPA, effective through September 2025, further streamlines the VA's acquisition of Horizon's rare disease and specialty treatments such as Ravicti, Buphenyl, Procysbi, and Uplizna. The VA has utilized these contracting vehicles to efficiently procure critical medications for provision through its integrated network of medical centers and clinics, supporting its mission to deliver comprehensive healthcare to America's veteran population.
Generated 2/5/25, 9:02 AM